| Name | Title | Contact Details |
|---|
Kite Pharma, founded in 2009, is dedicated to the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to fight tumor cells. Kite’s lead programs are in collaboration with the National Cancer Institute (NCI) and are being studied through the NCI’s Surgery Branch led by Steven A. Rosenberg, MD, PhD, who has pioneered immunotherapy approaches for cancer for more than two decades. This research has resulted in breakthrough clinical findings, including results from an NCI Phase 1/2a trial being presented at this year’s American Society of Hematology (ASH) Annual Meeting. Based on this progress and momentum, Kite plans to initiate a company-sponsored multicenter clinical program in aggressive non-Hodgkin’s lymphoma, with additional filings expected for other eACT™ products in diverse oncology indications.
Haupt Pharma is a Chesterfield, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We are dedicated to delivering excellent customer service as we build and maintain an environment that balances the needs of our valued employees and the organization. Our development of policies, programs, and services will promote accountability, involvement, diversity, and high performance, while ensuring compliance.
Smoky Lake - Family and Community Support Services is a Smoky Lake, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BERG is a Boston-based biopharma company focused on taking a bold “back to biology” approach to therapeutic discovery using its unique AI-based Interrogative Biology® platform. This platform combines patient biology and AI-based analytics to engage the differences between healthy and disease environments. The patient’s own biology drives the platform’s results and guides us in the discovery and development of drugs, diagnostics and healthcare applications. Our platform utilizes patient population health data to bring actionable Patient IntelligenceTM to precision medicine applications. For patients this means faster discovery and development of treatments, more effective precision treatments for individuals as well as a reduction in costs to our healthcare systems. BERG has a robust product portfolio in oncology, endocrinology and neurology with mature assets in oncology entering mid and late stage trials. BERG is committed to improving the lives of patients through precision medicine made possible by our innovative platforms.